#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Severe myoclonic epilepsy of infancy Arteriosclerosis Lip and/or oral cavity cancer Deafness neurosensory Dermatitis Small cell lung cancer recurrent Oesophageal carcinoma Primary amyloidosis Mantle cell lymphoma stage II Biotinidase deficiency Acute myeloid leukaemia Hereditary hypophosphataemic rickets Kawasaki's disease Burkitt's lymphoma Hypocalcaemia More trials…

    Learn about Rare Diseases

    Leiomyosarcoma recurrent Undifferentiated sarcoma – Trials in Disease Friedreich’s ataxia – Trials in Disease Alternating hemiplegia of childhood – Trials in Disease Andersen-Tawil syndrome – Treatment Indolent systemic mastocytosis – Trials in Disease Myxofibrosarcoma – Diagnostics Systemic mastocytosis Thrombotic thrombocytopenic purpura – Basic Information Undifferentiated sarcoma – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Pelareorep Exidavnemab Sodium Chloride Solution 0.9% Nafarelin Lomustine Pbf-999 VGA039 Vilobelimab ADCE-D01 Emiplacel Salbutamol Folic Acid, Anhydrous GS-4321 HYALURONIDASE OXYBUTYNIN HYDROCHLORIDE [68GA]GA-NOTA-AE105 AZD3632 Sodium Ascorbate Resatorvid Ammonium Chloride Bp More therapies…

    Learn about Your Condition

    Neurotrophic keratopathy Bile duct adenocarcinoma Hepatitis D Chronic hepatitis C Mucopolysaccharidosis I Suicidal ideation IgA nephropathy Otitis media Pyelonephritis acute Anaemia of chronic disease Follicular lymphoma stage II Hypertrophic scar Anorexia nervosa Axial spondyloarthritis Vestibular disorder More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Endometrial cancer recurrent

  • A study comparing Rinatabart Sesutecan to other treatments in patients with endometrial cancer who have previously received platinum-based chemotherapy and PD-L1 therapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • HUMAN IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST FOLR1 CONJUGATED TO 1-[(2R,3R,4R,5S,52S)-1,2,3,4,5-PENTAHYDROXY-52-{[(2S)-1-{[(2S)-5-CARBAMOYLAMINO-1-OXO-1-{3-[({[(1S,9S)-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL10,13-DIOXO-2,3,9,10,13,15-HEXAHYDRO-1H,12HBENZO[DE]PYRANO[3′,4′:6,7]INDOLIZINO[1,2-B]QUINOLIN-1-YL]CARBAMOYL}OXY)METHYL]ANILINO}PENTAN-2-YL]AMINO}-3-METHYL-1-OXOBUTAN-2-YL]CARBAMOYL}-7-[(2S,3R,4R,5R)-2,3,4,5,6-PENTAHYDROXYHEXYL]-46,54-DIOXO10,13,16,19,22,25,28,31,34,37,40,43-DODECAOXA-7,47,53-TRIAZANONAPENTACONTAN-59-YL]-2,5-DIOXOPYRROLIDIN-3-YL
    • Doxorubicin Hydrochloride
    • Paclitaxel
    Belgium Denmark Finland France Germany Greece +5

  • A study comparing BNT323 with chemotherapy in patients with HER2-expressing recurrent endometrial cancer who received previous treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Endometrial cancer
    • Endometrial cancer recurrent
    Investigated Drugs:
    • Db-1303
    • Docetaxel
    • Doxorubicin Hydrochloride
    Austria Belgium Czechia Denmark Finland France +9

  • Study on Dostarlimab and Niraparib for Patients with Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Endometrial cancer
    • Endometrial cancer recurrent
    • Ovarian cancer
    Investigated Drugs:
    • Dostarlimab
    • Niraparib Tosilate Monohydrate
    France Italy Spain

  • A Phase 3 Randomized Open-Label Study of Sacituzumab Govitecan Versus Physician’s Choice in Recurrent or Persistent Endometrial Cancer Post-Chemotherapy and Immunotherapy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Endometrial cancer recurrent
    Investigated Drugs:
    • Sacituzumab Govitecan
    • Doxorubicin Hydrochloride
    Czechia France Germany Greece Italy Poland +1

  • Study on the Safety and Effectiveness of IMGN151 for Women with Recurrent Endometrial and Ovarian Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Cervix carcinoma recurrent
    • Endometrial cancer recurrent
    • Fallopian tube cancer
    Investigated Drugs:
    • Brimonidine Tartrate
    • Imgn151
    • Prednisolone Acetate
    Belgium France Germany Ireland Italy The Netherlands +1

  • Study on Durvalumab, Olaparib, and Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer in Spain

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Durvalumab
    • Olaparib
    Spain
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!